Your browser doesn't support javascript.
loading
The role of proteomics in the age of immunotherapies.
Hayes, Sarah A; Clarke, Stephen; Pavlakis, Nick; Howell, Viive M.
Afiliação
  • Hayes SA; Bill Walsh Translational Cancer Research Laboratory, Hormones and Cancer, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Sydney, Australia. sarah.hayes@sydney.edu.au.
  • Clarke S; Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. sarah.hayes@sydney.edu.au.
  • Pavlakis N; Bill Walsh Translational Cancer Research Laboratory, Hormones and Cancer, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, Sydney, Australia.
  • Howell VM; Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Mamm Genome ; 29(11-12): 757-769, 2018 12.
Article em En | MEDLINE | ID: mdl-30046851
The antigenic landscape of the adaptive immune response is determined by the peptides presented by immune cells. In recent years, a number of immune-based cancer therapies have been shown to induce remarkable clinical responses through the activation of the patient's immune system. As a result, there is a need to identify immune biomarkers capable of predicting clinical response. Recent advances in proteomics have led to considerable developments in the more comprehensive profiling of the immune response. "Immunoproteomics" utilises a rapidly increasing collection of technologies in order to identify and quantify antigenic peptides or proteins. This includes gel-based, array-based, mass spectrometry (MS), DNA-based, or computer-based (in silico) approaches. Immunoproteomics is yielding an understanding of disease and disease progression, vaccine candidates, and biomarkers to a depth not before understood. This review gives an overview of the emerging role of proteomics in improving personalisation of immunotherapy treatment.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoma / Proteômica / Imunidade Adaptativa / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteoma / Proteômica / Imunidade Adaptativa / Imunoterapia Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article